What is Valion Bio, Inc. (VBIO) stock price today?

Valion Bio, Inc. (VBIO) is currently trading at $2.14, down 3.17% today.

What is VBIO P/E ratio?

Valion Bio, Inc.'s P/E ratio is -0.05. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is VBIO return on equity (ROE)?

Valion Bio, Inc.'s return on equity (ROE) is -165.44%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Valion Bio, Inc.'s market cap?

Valion Bio, Inc. has a market capitalization of $8.86M.

— · Biotechnology

Valion Bio, Inc. (VBIO) Stock

$2.14 -3.17% —: VBIO Healthcare

Valuation

Metric	Value
Price	$2.14
Market Cap	$8.86M
P/E Ratio	-0.05
P/B Ratio	0.03
P/S Ratio	-68.76
EPS (TTM)	$-0.02
52-Week High	$78.75
52-Week Low	$2.05
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-165.44%
ROA	-57.74%
ROCE	-56.13%
Gross Margin	25.75%
Operating Margin	-75.92%
Net Margin	3.11%
Debt/Equity	1.46
Current Ratio	0.57

Annual Financials (USD)

Metric	2017	2018	2019	2020	2021
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-3.0M	$-4.0M	$-5.0M	$-4.0M	$-2.0M
Net Profit	$-5.0M	$-4.0M	$-20.0M	$-4.0M	$-1.0M
EPS	$-0.38	$-0.19	$-0.61	$-0.09	$-0.02
Op Margin	-2125.1%	-4292.9%	—	—	—

Balance Sheet (USD)

Metric	2017	2018	2019	2020	2021
Total Assets	$1.0M	$1.0M	$6.0M	$3.0M	$1.0M
Total Liabilities	$1.0M	$0	$1.0M	$1.0M	$0
Cash	$1.0M	$1.0M	$6.0M	$2.0M	$1.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Valion Bio's Entolimod Accepted for Regulatory Review in Ukraine MT Newswires · Jul 22, 2026 Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway PR Newswire · Jul 22, 2026 World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market PR Newswire · Jul 20, 2026 Valion Bio Advances Entolimod Program with Government Engagement, Manufacturing Scale-Up, Oncology Supportive Care Plans MT Newswires · Jul 14, 2026 Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion PR Newswire · Jul 14, 2026

Cash Flow (USD)

Metric	2017	2018	2019	2020	2021
Operating Cash Flow	$-1.0M	$-3.0M	$-4.0M	$-4.0M	$-2.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$2.0M	$2.0M	$9.0M	$0	$0
Net Cash Flow	$1.0M	$0	$5.0M	$-4.0M	$-2.0M
Free Cash Flow	$-1.0M	$-3.0M	$-4.0M	$-4.0M	$-2.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-1.64
FCF Yield	-136.80%
Quick Ratio	0.86
Interest Coverage	-12.33
Return 1Y	-88.47%
Return 3Y	-99.58%
Return 5Y	—

Ownership

Insiders Held3.34%

Institutions Held22.00%

Institutions Float Held22.76%

Institutional Holder	Shares	Report Date
Lasry, Marc	101,638	2025-09-30
Geode Capital Management, LLC	87,818	2026-03-31
Sanctuary Advisors, LLC	61,205	2026-03-31
Marex Group Plc	59,263	2026-03-31
HRT Financial LP	42,419	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$336.64	-1.11%	38.93	$4.94T	0.32%
MSFTMicrosoft Corporation	$535.07	+2.38%	28.68	$3.97T	0.76%
GOOGLAlphabet Inc.	$351.66	+0.97%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$262.43	+3.29%	19.82	$2.82T	0.00%
METAMeta Platforms, Inc.	$718.67	-0.31%	27.93	$1.83T	0.28%

About Valion Bio, Inc.

Valion Bio, Inc. is led by CEO Michael R. Cavanaugh CPA,, employs 3 people, headquartered in US, publicly traded since 2008.

Valion Bio, Inc. (VBIO) stock trades at $2.14 with a market capitalization of $8.86M. The stock is valued at a price-to-earnings (P/E) ratio of -0.05, price-to-book of 0.03, price-to-sales of -68.76. Over the past 52 weeks the stock has ranged between $2.05 and $78.75, and currently trades 97.3% below its 52-week high.

On profitability, Valion Bio, Inc. generates a return on equity (ROE) of -165.44%, return on capital employed of -56.13%, an operating margin of -75.92%, a net profit margin of 3.11%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides